65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 5,072
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David Loew | MD, CEO & Director | 2.38M | N/A | 1967 |
Mr. Aymeric Le Chatelier | Exec. VP & Group CFO | N/A | N/A | 1969 |
Dr. Aidan Murphy Ph.D. | Exec. VP of Technical Operations | N/A | N/A | 1966 |
Mr. Craig Marks | Vice-Pres of Investor Relations | N/A | N/A | N/A |
Mr. Francois Garnier | Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer | N/A | N/A | 1962 |
Ms. Gwenan White | Exec. VP of Communications, Public Affairs & Sustainability | N/A | N/A | N/A |
Mr. Regis Mulot | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
Ms. Dominique Bery | Head of Nordics & Baltics | N/A | N/A | 1971 |
Dr. Yan Moore M.D. | Sr. VP & Head of Oncology Therapeutic Area | N/A | N/A | 1967 |
Dr. Alexander McEwan | Vice-Pres & Head of Radiopharmaceuticals | N/A | N/A | N/A |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Ipsen S.A.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 6.